Keyword: U.S. Federal Trade Commission
After months of regulatory scrutiny, the EU has given AbbVie and Allergan's $63 billion merger its first go-ahead in anticipation of an FTC decision.
Roche's $4.3 billion Spark Therapeutics deal is a poster child for extra antitrust scrutiny on biopharma M&As in 2019.
Exiting animal health is the last and largest piece of adjustment in Bayer’s organizational shake-up launched in November 2018. After weeks of rumor, Bayer finally confirmed on Aug. 20 that it’s selling the franchise to Eli Lilly spinoff Elanco for $7.6 billion.
Amgen buying psoriasis drug Otezla is a byproduct of the merger between Bristol-Myers Squibb and Celgene.
When the AbbVie/Allergan deal was unveiled in June, Allergan investors cheered, as AbbVie’s stock price sank. Analysts also have their doubts. While most viewed it as welcome news for Allergan, dubbing it a “graceful exit” for a “beaten-up name,” they raised multiple folds of concerns for AbbVie, the buyer.
The year 2019 kicked off with the biopharma industry’s largest acquisition proposal ever: Bristol-Myers Squibb unveiled it would buy Celgene in a cash and stock deal valued at $74 billion.
The FTC's scrutinizing pipeline overlaps and zeroing in on niche markets. Pressure from the Hill to broaden the review scope shouldn't be overlooked.
The 5-0 vote from the five commissioners could ease concerns that the agency has adopted a more stringent criterion in reviewing biopharma M&As.
Though the U.S. FTC has yet to deliver its verdict, the CMA stated that the two authorities have “cooperated closely” in their reviews.
After a year flush with big deals, pharma M&A watchers may be disappointed in the coming year with a smaller market for transactions, an analyst said.